Skip to main content

Table 1 Characteristic of patients

From: Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells

Patient#

Age/Sex

FAB

WBC(*109/L)

%CD34 in BMC*

Source

Cytogenetics

P1

35 Y/M

M2

9.09

67.3

BM

46 XY

P2

60 Y/M

M2b

15.80

72.1

BM

46 XY, t(8;21),AML1/ETO #

P3

46 Y/M

M5

12.00

56.0

BM

46 XY

P4

17 Y/M

M5b

3.39

89.1

BM

46 XY

P5

28 Y/M

M2b

11.37

76.3

BM

46 XY, t(8;21),AML1/ETO #

P6

20 Y/M

M1

10.03

70.1

BM

46 XY

P7

78 Y/M

M4

101.08

52.1

PB

46 XY inv (16)(p13q22)

P8

72 Y/F

M2a

1.95

31.5

PB

46 XX

P9

54 Y/M

M1

103.79

62.8

BM

46 XY

  1. P patient, Y year, M male, FAB French-American-British, WBC white blood cells, BMC bone marrow cells, BM bone marrow, PM peripheral blood.*Percentage of CD34+ cells in bone marrow cells of AML patients before sorting. # The t (8; 21) (q22; q22) chromosomal translocation gives rise to the AML1/ETO fusion oncoprotein